ABSTRACT
An antiserotoninergic drug cyproheptadine was administered to 10 patients at a dose of 4 mg per os to study LH, FSH and testosterone regulation in patients with polycystic ovaries. Blood samples were taken in the morning before, and 1 and 2 h after drug administration. A significant decrease in the level of testosterone (p less than 0.0001) in 1 and 2 h and a tendency to a decrease in the LH level and a LH/FSH ratio in 2 h after cyproheptadine administration were revealed. The effect of the drug on the FSH level was insignificant. A conclusion was made of the involvement of the serotoninergic mechanisms in the regulation of androgenic secretion in patients with polycystic ovaries.
Subject(s)
Cyproheptadine/therapeutic use , Follicle Stimulating Hormone/blood , Luteinizing Hormone/blood , Polycystic Ovary Syndrome/drug therapy , Testosterone/blood , Drug Evaluation , Female , Humans , Polycystic Ovary Syndrome/blood , Time FactorsABSTRACT
Gonadotropic function was investigated and the diagnostic value of the test with luteinizing hormone releasing factor (LHRF) was assessed in patients with polycystic ovaries. For this purpose a 100 micrograms dose of LHRF was intravenously jet injected to 10 patients with nonspecific polycystic ovaries. Levels of luteinizing and follicle stimulating hormones (LH and FSH) were determined before the injection and 15, 30, 60, 90 or 120 minutes after it. Patients with nonspecific polycystic ovaries compared with those who had specific pattern of the disease or with normal women showed elevated basal LH levels which significantly increased in response to LHRF administration. In patients with specific form of the disease the FSH response to the injection was inhibited while LN basal levels as well as its response to LHRF were the same as in healthy women. In 13 out of 15 patients (3 out of 4 amenorrheic females among them) the preparation displayed its ovulatory affect after a single diagnostic dose. Desirability of LHRF use for a differential diagnosis of polycystic ovaries or for therapeutic stimulation of ovulation was suggested.
Subject(s)
Gonadotropin-Releasing Hormone , Polycystic Ovary Syndrome/diagnosis , Diagnosis, Differential , Evaluation Studies as Topic , Female , Follicle Stimulating Hormone/blood , Humans , Luteinizing Hormone/blood , Male , Polycystic Ovary Syndrome/blood , Time FactorsABSTRACT
An increase in the prolactin basal level was detected in 8 out of 50 patients with ovarian polycystosis. A test with TRH and a simultaneous determination of the levels of prolactin, TTH, T3, T4 were used in 25 patients, of them a hyperergic reaction of prolactin to TRH was detected in 5. A correlation analysis of function of the thyroid was performed. Positive correlation between the levels of prolactin and TTH in patients with hyperprolactinemia and between a maximum increment in percentage to the initial level of TTH and prolactin in patients with a hyperergic reaction of prolactin to TRH was revealed. A conclusion was made of the common nature of disorder in the mechanisms of regulation of prolactin and thyroid function in patients with ovarian polycystosis.
